OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Increasing molecular diversity is creating a need for the reinvention of process development and control strategies.
Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.
There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.
December 14, 2022
Deeper biological understanding and technology innovations have improved the fate of ADC development.
Through the integration of human expertise, artificial intelligence, and automation robotics, bio/pharma companies can more efficiently target drug discovery efforts with bigger payoff.
December 12, 2022
Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.
The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.
December 01, 2022
Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.
Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.
November 21, 2022
Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.
November 17, 2022
A novel mathematical approach for fitting concentration-response curves is proposed that offers a more accurate estimation of potency data.
November 08, 2022
Companies need to consider and address formulation challenges to employ a successful reformulation strategy.
November 02, 2022
New medications show exciting outcomes for weight loss.